BioInvent International (BINV) BioStock Life Science Summit 2026 summary

Pipeline and immunotherapy rationale

• Four clinical programs are ongoing, mostly around Phase II, with emerging efficacy signals; discovery, GMP manufacturing and clinical development capabilities support internally prioritized progression.

• Immune-activating antibodies can produce durable responses across cancers, but activity is concentrated in immune-infiltrated “hot” tumors; cold tumors remain a major unmet need.

• BI-1808 targets TNFR2 and is intended to recruit immune cells into cold tumors, potentially broadening the reach of checkpoint therapies across cancer types.

• Preclinical work indicated that BI-1808 activates suppressive myeloid cells, promotes CD8-positive T-cell infiltration and can synergize with anti-PD-1 agents such as pembrolizumab.

BI-1808 evidence and combination strategy

• In a gastrointestinal stromal tumor example, CD8-positive T cells infiltrated and activated after five weeks of treatment; all four target lesions regressed on single-agent BI-1808.

• Responses were also observed in ovarian and lung cancer; ovarian cancer was selected as a lead setting for combination studies with anti-PD-1.

• Tumor analyses showed immune changes with BI-1808 alone, often enhanced with anti-PD-1; in roughly 35 patients studied, ~25% appeared to respond to the combination, across ovarian subtypes, with durable responses.

• Single-agent dose escalation produced no adverse events above Grade 2; adding BI-1808 to PD-1 treatment showed a similar tolerability profile to PD-1 alone.

• Preclinical studies are assessing combinations with antibody-drug conjugates; the proposed opportunity spans solid cancers and multiple approved or emerging therapies.

Competitive positioning and next steps

• The presentation framed immune modulation as a potential route to durable survival alongside therapies such as ADCs, which can produce high response rates but may face resistance; BI-1808 is being evaluated as a combination partner.

• The key milestone for the coming year is to demonstrate that BI-1808 can be safely added to the recently approved ovarian-cancer immunotherapy regimen, with the aim of improving activity as seen in animal models.

• In Q&A, the CSO said BI-1808 also has single-agent activity, with response rates comparable across studied cancer types to those expected from anti-PD-1; safety may enable combination dosing without reducing efficacy.

• Biomarker research is an active focus; the stated value proposition is improved response durability and overall survival, not only higher initial response rates.